Discover how Avigen’s avidity-based platform accurately detects, sorts and isolates high-performing TCR T cells, revealing that avidity reliably predicts cytotoxic killing and T cell activation — delivering mechanistic insight that conventional cytotoxicity assays cannot provide. Download the full case study to learn how our approach enables faster, de-risked TCR T cell candidate selection for immunotherapy development.
Assessment of cell engager-mediated T cell target engagement and function
Discover how Avigen’s avidity-based microfluidic platform resolved inconclusive cytotoxicity data for Etcembly’s novel tri-specific and bi-specific T cell engagers, delivering mechanism-of-action insights and a clear, rank-ordered comparison of cell engager performance against melanoma targets that standard endpoint assays could not provide. Download the full case study to learn how paired avidity and functional data enables confident, de-risked cell engager selection for immunotherapy development.